Certara, Inc. (NASDAQ:CERT - Free Report) - Equities researchers at William Blair increased their Q1 2025 earnings estimates for shares of Certara in a research report issued on Monday, April 14th. William Blair analyst M. Smock now forecasts that the company will post earnings of $0.07 per share for the quarter, up from their previous estimate of $0.06. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Certara's current full-year earnings is $0.28 per share. William Blair also issued estimates for Certara's Q4 2025 earnings at $0.07 EPS.
CERT has been the subject of several other reports. TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Barclays reduced their target price on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. KeyCorp lifted their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday. Robert W. Baird raised their target price on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Finally, Stephens reiterated an "overweight" rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $15.17.
Check Out Our Latest Report on CERT
Certara Stock Performance
CERT stock traded up $0.62 during midday trading on Wednesday, hitting $14.15. 2,114,112 shares of the company traded hands, compared to its average volume of 1,188,632. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business has a 50 day simple moving average of $11.62 and a 200-day simple moving average of $11.46. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -70.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. Certara has a twelve month low of $8.64 and a twelve month high of $17.94.
Institutional Investors Weigh In On Certara
A number of hedge funds and other institutional investors have recently made changes to their positions in CERT. Versant Capital Management Inc raised its stake in shares of Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the period. Venturi Wealth Management LLC lifted its stake in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after acquiring an additional 2,509 shares in the last quarter. Wells Fargo & Company MN boosted its position in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. bought a new position in shares of Certara during the 4th quarter worth approximately $47,000. Finally, Blue Trust Inc. raised its holdings in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.
About Certara
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Read More
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
